Astrazeneca Plc will acquire US based Alexion Pharmaceuticals in a $39 billion deal, the company said in a statement on Saturday. Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares per Alexion share, the company said.
(photo credit: JPOST STAFF)